Vriens D - Search Results

1

Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?

de Koster EJ, Sulaiman T, Hamming JF, Schepers A, Snel M, van Velden FHP, de Geus-Oei LF, Vriens D. de Koster EJ, et al. Among authors: vriens d. Diagnostics (Basel). 2021 Mar 19;11(3):553. doi: 10.3390/diagnostics11030553. Diagnostics (Basel). 2021. PMID: 33808843 Free PMC article.

2

Tailoring therapy in colorectal cancer by PET-CT.

Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ. Vriens D, et al. Q J Nucl Med Mol Imaging. 2009 Apr;53(2):224-44. Q J Nucl Med Mol Imaging. 2009. PMID: 19293770 Free article. Review.

3

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.

de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. de Geus-Oei LF, et al. Among authors: vriens d. J Nucl Med. 2009 May;50 Suppl 1:43S-54S. doi: 10.2967/jnumed.108.057224. J Nucl Med. 2009. PMID: 19403879 Free article. Review.

4

Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies.

Vriens D, de Geus-Oei LF, van Laarhoven HW, Timmer-Bonte JN, Krabbe PF, Visser EP, Oyen WJ. Vriens D, et al. Nucl Med Commun. 2009 Jul;30(7):550-7. doi: 10.1097/MNM.0b013e32832bdc80. Nucl Med Commun. 2009. PMID: 19424100 Clinical Trial.

5

Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.

Vriens D, van Laarhoven HW, van Asten JJ, Krabbe PF, Visser EP, Heerschap A, Punt CJ, de Geus-Oei LF, Oyen WJ. Vriens D, et al. J Nucl Med. 2009 Nov;50(11):1777-84. doi: 10.2967/jnumed.109.064790. Epub 2009 Oct 16. J Nucl Med. 2009. PMID: 19837750 Free article. Clinical Trial.

6

A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment.

Vriens D, de Geus-Oei LF, Oyen WJ, Visser EP. Vriens D, et al. J Nucl Med. 2009 Dec;50(12):1933-9. doi: 10.2967/jnumed.109.065243. Epub 2009 Nov 12. J Nucl Med. 2009. PMID: 19910436 Free article.

7

Methodological considerations in quantification of oncological FDG PET studies.

Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Vriens D, et al. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1408-25. doi: 10.1007/s00259-009-1306-7. Epub 2009 Nov 20. Eur J Nucl Med Mol Imaging. 2010. PMID: 19936745 Free PMC article. Review.

8

The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

Dijkman BG, Schuurbiers OC, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JN, Snoeren MM, Oyen WJ, van der Heijden HF, de Geus-Oei LF. Dijkman BG, et al. Among authors: vriens d. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2037-47. doi: 10.1007/s00259-010-1505-2. Epub 2010 Jun 10. Eur J Nucl Med Mol Imaging. 2010. PMID: 20533031 Free PMC article.

9

Comparison of two region of interest definition methods for metabolic response evaluation with [18F]FDG-PET.

Vriens D, De Geus-Oei LF, Van Laarhoven HW, Van Der Heijden HF, Krabbe PF, Visser EP, Oyen WJ. Vriens D, et al. Q J Nucl Med Mol Imaging. 2010 Sep 8. Online ahead of print. Q J Nucl Med Mol Imaging. 2010. PMID: 20827254

10

Comparison of two region of interest definition methods for metabolic response evaluation with [¹⁸F]FDG-PET.

Vriens D, De Geus-Oei LF, Van Laarhoven HW, Van Der Heijden HF, Krabbe PF, Visser EP, Oyen WJ. Vriens D, et al. Q J Nucl Med Mol Imaging. 2010 Dec;54(6):677-88. Q J Nucl Med Mol Imaging. 2010. PMID: 21221073

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters